Verve Therapeutics Ratios and Metrics

Market cap in millions CAD. Fiscal year is December - November.

Millions CAD. Fiscal year is Dec - Nov.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2020
Period Ending	Aug '25 Aug 1, 2025	Nov '24 Nov 30, 2024	Nov '23 Nov 30, 2023	Nov '22 Nov 30, 2022	Nov '21 Nov 30, 2021	Nov '20 Nov 30, 2020	2016 - 2020
Market Capitalization	22	18	78	93	139	17	Upgrade
Market Cap Growth	-73.06%	-76.38%	-15.91%	-33.28%	739.55%	-45.17%	Upgrade
Enterprise Value	21	14	70	88	138	20	Upgrade
Last Close Price	0.07	0.06	0.24	0.32	0.55	0.10	Upgrade
PB Ratio	6.03	3.21	1.44	1.74	3.20	0.51	Upgrade
P/TBV Ratio	6.03	3.21	1.44	1.74	3.20	0.51	Upgrade
Debt / Equity Ratio	-	-	0.00	0.00	0.01	0.11	Upgrade
Quick Ratio	2.40	7.96	6.58	8.06	3.62	0.06	Upgrade
Current Ratio	2.87	8.35	7.25	8.26	4.04	0.07	Upgrade
Return on Equity (ROE)	-174.55%	-173.41%	-19.33%	-9.62%	-24.64%	-16.90%	Upgrade
Return on Assets (ROA)	-98.00%	-95.19%	-12.14%	-12.95%	-6.13%	-10.13%	Upgrade
Return on Capital (ROIC)	-99.79%	-97.19%	-12.46%	-14.19%	-6.82%	-10.73%	Upgrade
Earnings Yield	-216.56%	-282.66%	-13.33%	-5.01%	-6.73%	-32.08%	Upgrade
FCF Yield	-	-28.37%	-9.82%	-7.79%	-3.98%	-15.22%	Upgrade
Buyback Yield / Dilution	-3.49%	-4.05%	-17.95%	-30.28%	-35.83%	-14.73%	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.